Bactiguard prices its initial public offering at SEK 38 per B share – trading commences on NASDAQ OMX Stockholm today

        Print
| Source: Bactiguard Holding AB
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA,
AUSTRALIA, CANADA, HONG KONG OR JAPAN.

Bactiguard Holding AB (publ) (“Bactiguard” or “The Company”) hereby announces
the outcome of the offer to acquire shares in Bactiguard and listing on NASDAQ
OMX Stockholm (“the Offer”).

Interest in the Offer has been substantial, both among Swedish and international
investors and among the public in Sweden. The Offer was oversubscribed, and
trading in the Company's shares on NASDAQ OMX Stockholm starts today.

Outcome of the Offer in brief:

  ·
The final price of the Offer has been set at SEK 38 per B share

  ·
The outcome of the Offer comprises a total of 10,922,244 B shares, of which
6,305,573 newly-issued B shares and 4,616,671 existing B shares

  ·
An additional 1,638,336 B shares may be sold by the Company's principal owners,
Thomas von Koch through Bactiguard B.V. and Christian Kinch through KK Invest
AB, to cover the over-allocation (”The Over-Allocation
Option”)[1] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20init
i 
al%20public%20offering%202014-06-19.docx#_ftn1)

  ·
The listing concludes the offset offer to bond holders in the Company. In total,
bonds equivalent to a nominal value of SEK 222.5 million are being set-off to B
shares

  ·
The total value of the Offer amounts to approximately SEK 415 million
(approximately SEK 477 million if The Over-Allocation Option is exercised to its
full extent), of which approximately SEK 240 million is injected as issue
proceeds to The Company for the newly issued B shares (before issue costs) and
approximately SEK 175 million is related to B shares which have been sold by
bond holders that have chosen to convert their bonds into B shares in the set
-off issue

  ·
The principal owners have decided to reduce the number of existing shares in the
offer, which decreases the Offer by approximately SEK 216 million from what has
previously been communicated

  ·
Following the Offer, the total number of B shares in Bactiguard amounts to
29,302,373 and the total number of A shares to 4,000,000

  ·
Based on the final price of the Offer, the value of all Bactiguard's shares
amounts to approximately SEK 1,265 million

  ·
The shares have been allocated to international and Swedish institutional
investors and to the public in Sweden

  ·
Following the Offer, Bactiguard will have approximately 2,700 shareholders

  ·
Trading in the Bactiguard share on NASDAQ OMX Stockholm will commence today, 19
June 2014, under ticker symbol
"BACTI"[2] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20initi
a 
l%20public%20offering%202014-06-19.docx#_ftn2)

Quote from Johan Rugfelt, CEO of Bactiguard:

”Bactiguard’s mission is to prevent healthcare-related infections, reduce the
use of antibiotics and save lives by developing and manufacturing infection
preventive healthcare products. In recent years we have concentrated on
developing our own product portfolio and building up a global network of
distributors. With the listing of Bactiguard, the final piece of the puzzle
falls into place as this provides us with the financial strength necessary to
genuinely realise the vigorous growth that we see ahead of us.”

Quote from Christian Kinch, Chairman of Bactiguard’s board of directors and
principal owner:

”Bactiguard's journey so far has been fantastic, from technical innovation and a
licensing business to an international medtech company with its own product
portfolio. During the subscription period we have experienced great interest in
Bactiguard, from both the public and institutions, and it is gratifying that the
offer has been oversubscribed. However, we have received requests from many
investors that we, as principal owners, should retain a larger shareholding than
was initially deemed appropriate. We have therefore decided to reduce the number
of existing shares being sold. We see great potential in Bactiguard, and we look
forward to participating in the company's continued development and value growth
together with new shareholders.”

Swedbank has acted as Lead Manager and Sole Bookrunner and ABG Sundal Collier
has acted as Co-Lead Manager in connection with the IPO. Cederquist is legal
advisor and Lenner & Partners is financial advisor to the Company.

This is information that Bactiguard Holding AB (publ) is required to publish in
compliance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on 19
June 2014, at 07.00.

----------------------------------------------------------------------

[1] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20initial%20pu
b 
lic%20offering%202014-06-19.docx#_ftnref1) The over-allocation option can be
exercised, on one or more occasions, entirely or in part, by the Lead Manager as
the stabilising manager, during a period of 30 days from the first day of
trading in the Company's B shares on NASDAQ OMX Stockholm.

[2] (http://file///C:/Users/ced/Desktop/Bactiguard%20prices%20its%20initial%20pu
b 
lic%20offering%202014-06-19.docx#_ftnref2) Trade in the Bactiguard share on
NASDAQ OMX Stockholm until 25 June 2014 is conditional upon fulfilment of the
terms of the offer.
For further information, please contact:

Johan Rugfelt - CEO
johan.rugfelt@bactiguard.se
+46 708 724 739

Fredrik Järrsten - CFO
fredrik.jarrsten@bactiguard.se
+46 72 550 00 89

Cecilia Edström - Director of Communications
cecilia.edstrom@bactiguard.se
+46 722 262 328
Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare
associated infections, reducing the use of antibiotics and saving lives by
developing and supplying infection prevention solutions to the healthcare
industry. The company’s patented coating prevents healthcare associated
infections by reducing bacterial adhesion and growth on medical devices.
Bactiguard®-coated urinary catheters are market leading in the US and Japan, and
in recent years the company has developed its own product portfolio of coated
catheters for the urinary and respiratory tract and the blood stream. Bactiguard
is currently in a strong expansion phase, focused on new markets in the EU,
Middle East, Asia and South America. The company reported  sales of
approximately SEK 130 million in 2013, has 60 employees, headquarters in
Stockholm and production facilities in Markaryd and Malaysia.